Some hopes and concerns regarding medical event-reporting systems - Lessons from the NASA Aviation Safety Reporting System

被引：0
|
作者：
Billings, CE [1 ]
机构：
[1] Ohio State Univ, Cognit Syst Engn Lab, Columbus, OH 43210 USA
来源：
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE | 1998年 / 122卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [41] Real-world safety evaluation of brivaracetam: insights from the US FDA Adverse Event Reporting System
    Meng, Zenan
    Li, Xinzhi
    Liao, Yue
    Feng, Feng
    Wang, Tingting
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [42] Post-marketing safety profile of cannabis products: Signals from the FDA adverse event reporting system
    Giunchi, Valentina
    Fusaroli, Michele
    Lunghi, Carlotta
    Zongo, Arsene
    Raschi, Emanuel
    Poluzzi, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 222 - 223
  • [43] Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
    Kong, Wenqiang
    Mao, Wei
    Zhang, Lin
    Wu, Yanyan
    FRONTIERS IN PEDIATRICS, 2023, 10
  • [44] Triptans and Serious Cardiovascular Events: Possible Safety Signals from the FDA Adverse Event Reporting System Database
    Roberto, Giuseppe
    Piccinni, Carlo
    Biagi, Chiara
    Koci, Ariola
    Motola, Domenico
    Vaccheri, Alberto
    Montanaro, Nicola
    Poluzzi, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 438 - 438
  • [45] Recombinant hepatitis B vaccination of neonates and infants: Emerging safety data from the vaccine adverse Event Reporting System
    Niu, MT
    Davis, DM
    Ellenberg, S
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (09) : 771 - 776
  • [46] Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System
    Kreimeyer, Kory
    Dang, Oanh
    Spiker, Jonathan
    Munoz, Monica A.
    Rosner, Gary
    Ball, Robert
    Botsis, Taxiarchis
    COMPUTERS IN BIOLOGY AND MEDICINE, 2021, 135
  • [47] Real-world safety evaluation of atorvastatin: insights from the US FDA adverse event reporting system (FAERS)
    Wan, Hongbing
    Xu, Xiuxiu
    Yi, Dasong
    Shuai, Kexin
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (03) : 305 - 314
  • [48] Two-year review of hepatitis A vaccine safety: Data from the Vaccine Adverse Event Reporting System (VAERS)
    Niu, MT
    Salive, M
    Krueger, C
    Ellenberg, SS
    CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) : 1475 - 1476
  • [49] Importance of swift event adjudication of endpoints for adequate reporting to data and safety monitoring boards in clinical trials—lessons from CULPRIT-SHOCK
    Peter Clemmensen
    Benedikt Schrage
    Uwe Zeymer
    Holger Thiele
    Karl Wegscheider
    Trials, 22
  • [50] Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database
    Michael Irizarry
    Ilona Surick
    Ari Michael
    Lynn D. Kramer
    Alzheimer's Research & Therapy, 17 (1)
12345